Aurinia Pharmaceuticals (AUPH) 2 May 242024 Q1 Earnings call transcript

Greetings, and welcome to the Aurinia Pharmaceuticals First Quarter 2024 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. It's now my pleasure to turn the conference over to Andrea Christopher, Head of Corporate Communications and Investor Relations for Aurinia Pharmaceuticals. Please go ahead, Andrea.

Thank you, operator, and thank you to everyone for joining today's call and webcast.

call Joe are Officer; Miller, the Chief Greenleaf, and on Officer; Executive our me this Peter morning Aurinia's Dr. Joining Chief Financial and quarter our Aurinia's company's as press Keenan, Chief this Officer. Today, the will Greg morning. issued Medical communicated in XXXX and financial review first release operational results we discuss its statements also on The this XX-Q filed company Form quarterly financial morning.

also website applicable Aurinia's Securities and For auriniapharma.com. U.S. Canadian authorities, more the Securities information, Aurinia's filings please with available which are refer at Commission and on to Exchange

During to forward-looking expectations. differ today's uncertainties statements based These forward-looking may Aurinia may call, make of and on statements a risks results current are significant actual subject and materially. number

Commission could Form XX-K and For annual press in with financial Aurinia's Form Aurinia's future business, XX-Q report Securities its on current to statements and unless and Canadian securities information its obligation the of today's a are the factors Exchange by X, results us. report as such quarterly law, based and U.S. no disclosures discussion and of currently otherwise statements. required Thursday, as release, that call assumes its on affect Aurinia XXXX, noted Except upon filings any recent please of all all May during and made to refer today, available to update authorities. Please note that are

CEO, Now call to Peter? Greenleaf. Peter and let the President turn me Aurinia's over

Miller, on to joining I'll focus over Thanks, additional want call. our Joe good on for performance. first headcount demonstrating thank cash us in that this on, on company today's the company's is the towards quarter, our provide the our rapidly company by results. the reflecting then including saw quarter and morning's flow execution, first approximately XX% Andrew, morning, financial positivity. accelerating the company's line commercial the and CFO, reducing continued call details time I we the everyone. On restructuring momentum to and focused everybody We turn strong solid call, initiatives will to

So these performance first into me quarter executing we're on initiatives. now overall dive business let the and how

For net USD approximately of of we approximately on net XX% our million million. Aurinia of With representing the track of growth $XX.X this to achieved growth $XX.X XXX million year-over-year. We representing in momentum, net in achieved revenue total first remain significant approximately XX%. XXXX, product to guidance USD quarter million product achieve XXX revenue, revenue, range

our and on XX, executed speed February focus of terms and following our while restructuring In precision growth. efforts, LUPKYNIS we the announcement maintaining with on

approaches AURXXX. While on for we've ceased development are AURXXX, exploring alternative currently we

the of for flexibility flow value over organization Taken provide increasing will a excluding the the whole, will meaningful share for company a the cash, expect restructuring to drive future. cash and allowing tangible and we as positive accumulation position time, repurchases more

of $XXX operating basis on range to million, operating million. be approximately quarter. headcount reduced $XX that company million in to part by be expenses restructuring, our this of employee total With As reduce The will expenses in XX% corporate million $XX year. cash-based we effort, a in the of over to first we XX approximately approximately this of expects $XXX with months expenses expect go-forward million next million to and by to $XXX annualized $XXX the XX% the recognized operating

of the cash XXXX achievements very positive, flow to that ahead these confirm With expect of to our share second be in projections. quarter mind, prior I'm in we excluding pleased repurchases

XX, pharmacy. added first with we quarter, the year key XXX these PSFs this representing Together, X,XXX hospital year-over-year LUPKYNIS patients first growth. There increase approximately PSFs in comparison and approximately of XX, to brand's approximately we driving metrics. front, of through are laser-focused XXX revenue trajectory. In substantial the realizable patients metrics was prior receiving March forms March remains several patient who our LUPKYNIS $XX,XXX improvements were as X,XXX an combination approximately in XXXX, XXX fills either LUPKYNIS than it initial restarting and hospital commercial for on as guidance all in And or restarts commercial and versus annualized on driven quarter, Net approximately the total therapy LUPKYNIS the higher start new in patient per XXXX, key driving On per XXX the patients overall of were an commercial by revenues patient on have of XX%. basis.

now start from has has the through the that approximately XXX be restarts XX, pricing will realizable we patients hospital annualized XXX in approximately year net new channel. in basis. April added on As per over XXXX, an evolved persistency the patient of to of revenue $XX,XXX believe the adherence PSFs company and From range time, $XX,XXX the and

We continue converting high XX% approximately sustain conversion patients with therapy. to of rates on PSFs to

We XX also within therapy sustained time approximately of with days. a rapid XX% starting patients conversion

XX approximately at adherence therapy overall to patients remaining first grew XX% therapy XX at from at Our XX% rates on through remained persistency months. remaining high on year-over-year XX% quarter approximately months of and the

XX above, therapy first our respectively. the are in and remained we of XX% and Additionally, Based reiterating quarter, full guidance. year on months, at XX all patients XX% on of the

Our metrics demonstrate the growth continued LUPKYNIS. upward driving that of trajectory is

financial most financial strength importance strong reflecting We several the achieved with for flexibility we treatment future. Along and a heading with cash with the strong that best-in-class recently the current towards as guidelines. flow and are increasing LUPKYNIS positivity performance, aligns clinical portfolio also drug milestones, a the of key this company's

established has update increase health of continue regular this is earlier population, lupus roughly Xx to believe clinical have necessary. Yet, includes additional label increase LN year. for underdiagnosed and every not X severity reduced As trials FDA indicating safety lupus are only still prioritize lupus for by and a receive significant understanding high are guidelines to proteinuria well campaign This in that faster from as steroids and diagnosing screens of the nephritis lupkinis potential among MMF language when need with proteinuria for not We label the MMF levels as every being years a has followed. on LUPKYNIS. The to lupus focused been launched data a of X that than treatment being an the them X achieved given them therapy alone. know We The that and understand renal the complete of aligns indicate to treatment patients untapped longer lupus among and minimum that the patients why glucocorticosteroids all seriousness post-hoc nephritis. no nephritis to our market. with visit urine rheumatologists to there at years, awareness treating sustained AURORA on Signs approved and patients for marketing lupus is protein beyond encouraging long-term screening of still of treatment about innovated the and nephritis current percentage we week, to levels necessity may X announced showed analysis we aggressively our keeping to lupus and improving steroids The people efficacy time label designed we're physicians and response of the now shown screening target receiving not want study. recently of a Current and throughout assessed at to heavily extension of guidelines. LUPKYNIS treating the a LN which X the includes the closely LUPKYNIS is point more kidney the when alone. Shifting urgent and patients. With efforts, underserved compared low-dose rheumatologists Know campaign new data actually

in access outside expand we're activities from LUPKYNIS to commercial also to key with Otsuka's Japan. continued another seeing Regarding Europe, in the working we're our market diligently regulatory and U.S., approval revenue launch pending activities to

on of treat previously XXXX noted, approval, to nephritis. Upon net of for their year receive adults November lupus As JNDA low a receive expect million from second approval regulatory response Otsuka to the filed double-digit that the to the of this LUPKYNIS of authorities sales $XX from the we launched. Japanese once in in half expect and we a active milestone with royalties regarding

take execution we in also nephritis. great accomplishments recognize living our we solid announced priorities. I work quarter May At our Aurinia, to do in business pride every awareness So is previously improve people to of lupus lives want believe with that we day against the month. the summary, reflect first lupus

difference of the questions at return call committed that. I'd the you to like a turn then Joe detailed review to the I'll for a to sight and results, recap any the and a to patient end over that for community, We now never have. call open we Joe? more for of but this financial line might lose making of are the quick

morning, good and Peter, you, everyone. Thank

for go March an ended LN million first XXXX QX of million of March Total XXXX. further were inclusive Let's the predominantly revenue into $XX.X $XX.X first to of XX, the by few million, driven in XXXX, cost sales XXXX. of burdened until was quarter and XX, late months fully XX, that was main charge pharmacies, quarter million note financial $XX.X respectively. and and standpoint revenue from the quarter as March representing It $XX.X in important fairly minutes take XXXX. increase and XX, for X detail of results onetime over our and an $XX charge a net ended operating quarter LUPKYNIS The XXXX, operating of ended market. Total million not same the and March restructuring primarily restructuring from the to was the XXXX, is first specialty penetration sales $XX.X expenses for the for respectively. Net is implemented was increase approximately X period our the quarter expense the and million due in XX% XX%, growth product regarding

as is compensation the million a was reflected the credit reduction share-based primary loss discussed in Cost quarter $X.X the related of XX, expenses XX% XX, moment. XX, prior was mentioned, quarter for for costs, $X.X the ended reflected of and was was The ended as decrease balance late March XX, into XXXX. Restructuring for of first denominated the expense of asset, other XXXX. XXXX, be XXXX. Interest onetime $X.X sales asset, $X.X was XXXX, quarter XXXX, with ended placed line Let first no onetime and prior reduction for most a for plant and primarily XXXX late March the The placed and and and general is $X.X is the the June me in and plant ended period. for expense period. Research decrease XXXX a March million of planned onetime $X.X and contract million which for share-based the a quarter which net for spend was The $X.X the quarter. Other the XXXX, the related expense for does $X.XX for give was to million to development was occurred is X due and the lower was charge. The June our operating the onetime in of expense in include rates. for March previously and in due expense in $XX.X restructuring for Swiss March compensation but were Aurinia of XX%. a line of margins costs million per first in expense reflects in the primary income year our and for operating interest $XX.X the efforts on was quarter the administrative million or per of the March for XXXX, is coupled March R&D as XX, employee million for XXXX, the of francs Noncash year XXXX, and million expenses, quarter million share-based employee-related and amounted drivers expense quarter million prior impact the costs. XX, year in headcount, benefit March in an restructuring increase XX, right-of-use due as loss though sales onetime March XX, for severance its is charge $X.X driver headcount, $XX.X occurred which pipeline and period ended our expense quarter the million increased to inclusive compensation to breakdown further increase for March the Selling, balance previously other late expense quarter quarter finance will to restructuring stand-alone to in item service within charge year compensation net were the included a now ended of share to yields both XX, approximately company inclusive XXXX. Gross programs XXXX, of period. and quarter item. Noncash March is not interest X. $XX.X LUPKYNIS, million our statement recorded a and of XXXX, early the million quarters impact interest million and changes $X.X The XX, SG&A for costs loss amortization travel. common up of expenses, SG&A compared to termination $X.XX restructuring $XX.X first prior the service $X.X common does fluctuations. charge, XX, ended respectively. The loss The mono March the of share-based right-of-use the exiting in of XXXX. share decrease XX, The and XXXX, increased XX, separately million has the quarter drivers income and expenses, mono or March primarily made finance in compensation $XXX,XXX The the ended million ended you $XXX,XXX into late of restructuring stand-alone to the net expenses of not the and compared for as a include higher quarter restructuring $X.X which related ended of ended XXXX. this profit and to investments income XX, months The is XXXX. decrease lower announced, corporate primarily March payments net and result interest share-based for loss recognized the as

The mono LUPKYNIS. partially at is As investment primarily commitments of restructuring-related LUPKYNIS, of activities payments, payments, of XX, XX, of share compared plant increase XXXX. in to cash Aurinia XXXX, repurchases million and an and $XXX.X restricted million post-approval equivalents cash had continued decrease December approved drug, cash, in cash related investments to our by and from March $XXX.X commercialization offset sales received and

would for debt remains Peter back remarks. like I hand XX, at free some the With March company closing over that, Peter? call The to XXXX. to

thank Joe. your Thanks, beyond. and I forward looking for to Obviously, in XXXX continued want today. time to we're strong performance all you

We have. the now questions might up open will for lines you any Operator?

[Operator Instructions]

coming Maurice from today from Jefferies. Raycroft first question is Recro Our

This is label. the updated the to wanted Farzin implications on for I on ask of Maury.

or influence Your the further the of expect that PSF Do to conversion has do in you to expect perception mid-XXs. for the rate prescribers we been drug? primary

that by original AURORA So for you of think update in agency of the we to the Listen, provided thank question. recognition the I addition study. -- label is the data a pivotal

indication to incorporated going and have it's language be think, anything help think to therapy have has be on I I not gets the the in we'll of to it X that conversion persistency year that on not X data X-year the at to and been and We're side equation, side but multiple approximately. both X beyond Probably probably as the drug more outlined fronts. the helpful concluded years looking of label guidelines is not studied. To on going in out see. utilized the -- that the ensuring KDIGO the us, ULR to the taken

and it to published see out data length there. already persistency and therapy the we more of additive as that's So

Okay. sense. month, PSS had last you that then accounted, and total Makes restarts. the XXX And like

XQ bit or So factors the than this the slowness is that a driving the monthly numbers. were there lumpiness trending lower any in Is April? average

Well, to the and restarts think, closer plus XXX. in exact I hospitals combination the number, was

think were quick just you probably the I was XXX. it doing math, So

week of in first we year. per lower, a consistent, the with at did look of were on basis consistent slightly the quarter you pretty first but the maybe in we XX the that what pretty weeks If versus it's where year,

but where 'XX, of you last in with it's were 'XX, PSF directly we just number on was that April year. a April look almost If at target

of of April XX% alone at versus look change by of in you driven year-over-year hospital PSF's The 'XX, PSFs very numbers patients. 'XX sort about the So on and month were big April restarts was in improvement driver consistent. if the in April both the

today question Next from TD Cowen. Stacy Ku is coming from

momentarily. few. We I a because kicked repeat got have if question a I off Sorry did

to question. the is was first believe First a follow-up I what

look is have then start That's And Just big first long-term evolving forward? your the question. in What's case of I hospital your thoughts important you talk about channel a few follow-ups. the how growth? as around the additions forms we can for current picture? purchases formulary and patient kind

X and let's business PSFs show it's But emergence I last, starts the as months this but call XX NRx, you've Obviously, it, see new question. think think think because of the emerging to since kind equivalent growth. of a best seen new But important. it's importance albeit patient of XX% as restarts the of right? lines convert, of hospital we of are of and an those smaller, great over I new I -- indicator patient volume. And

PSFs. We been which to patients PSFs major XX new mind, are on in my discount plus, growth. months hospital label a X our still lot change months. But to new X while the indeed these that. doing this from are focus the AURORA Stacy, And So patient not growth think combination about patients, points I'm new any it there, And is and come important all importance the in in the that's patients the of both the extension it, doesn't, last for study, therapy I any that's to identifying new it, way drug. all the our look last, call initiatives an I out and for primary have patient does is trying on marketing our patients getting and internally driver a we way we within let's the selling And that on quarter. talk the more the restarts, of discount need importance think think numbers of how the has over one. new of work [indiscernible] a way, indicator the we've But

the walk cadence your revenue expectations? to for kind and And feel you want you Understood. the about seasonality, about And remind revenue guidance just us end guidance, quarterly 'XX this how Okay. through, year? low high around then your of

Well, we sort and to numeric would just qualitatively have the end this speaking, the or the guidance the high we've growth dip summertime driven as think don't how the generally very then in we challenge that be and range for to you that, of quarter had to pillars low, little power we in and upper of range, with a to of the during the see some in X the end is If a any I be now, know, summer. Since flattening decline give or we going sort well it of bit of the think the seasons we have summertime. above can high quarter in of in produced the range. we summertime or think getting significant how the a but fourth by ability and the through to is that of the we perform back low end

look we to XQ table be be to think I to come on million the see that in range general But are driver outperforms, out. biggest a Lastly, to year summer going million year. And with the the for performance $XXX guidance and $XXX at back the will is and that where key year. about we'll where coming we see talk of swing the then the months

around And your for your exploring go more a us? last product, Okay. that But a follow-up Can mean? question into just little understand you approaches Understood. bit does alternative what comments XXX. us pipeline detail for help then just is on

Yes.

was in I difference commitments. pipeline those own AURXXX. we we but very have short Yes, commitments purchased we our between to from minimal, answer and XXX follow-on think the AURXXX have that do is it the

others the type that own for move to our seek else conversations we to either we the produce of don't would the or drug for someone the asset. drug we value through and in develop of see asset speed So type will the want would fact, the if, with on forward efficiently

the the more day in the we don't just think more But moving in data we to space BAF inhibitor, April to going much broadly, and and every April B-cell want So forward. in which more pathway other on disorders as place pertains it words, this and particular. a emerges not to get of shelve immunology it BAF obviously inhibitors for be bat IgAN value more April there's

or to keep in our else's. want own moving we So whether this it's hands someone thing forward,

Leerink is question Instructions] Our coming Joseph [Operator next Schwartz from Partners. from

now ask you have Congrats there and on the And how ongoing? How diagnosis. is on strong quarter. to been screening about to you being front? screening how done? around that initiatives starts And to other Where have the new move your that much much a progress wanted patient first I needle? initiatives relative able is contributing to is community

the question, Joe. for Thanks

we at in that And to of physician-reported of can AAU level, improvement urine some tell need that's we at think and I do awareness sort of been We're diagnose least is seeing seeing improvement series you one the have we're rheumatologist lupus done. patients what screens. some in treatment.

get patients, like every diagnosis. the you the well, proteinuria in positive than under get haven't at not lupus nephritis do XX% state around can And over low indicate seen of like least to try yet one, numbers to XX% and years. And guidelines submitted some record them a been urine that even several treated. a And proteinuria it claim have of come done these even they would that, to have Optum patient to looking a geez, large through why? claims numbers is the Joe, that by you patients. Only they is pull by there's as indeed was tell when these or time a of back, office. is to at reported say, that. a you lupus get guidelines What level one liberties years lupus even a of grossly is few our audit say couple get through historically I at kind take It's no patients actual interpretation of they you're thousand patients This should data. And what's We screen. direct. hundred of kind a lupus claims it's less have looking

and and lupus treat differently. proteinuria I nephritis I think just is awareness think hematologists will general one

proteinuria or proteinuria in several protein nephritis low they see -- see I nephritis. being of think the and lupus as indeed urine, grams they and not as

need a you're liberty patient but build doing the of forward, going moving the research Now the screens. indicative awareness it's bit work unless a you're of we never poor outcomes and to even that are from some low levels urine the little find for is to we've done, of it

I we're think to more there, impact forward. making the we So as come campaign continue

Yes, it seems in area for regarding updated like half. was space. our fair label, expectations, wondering were second ahead great think happened white a of amount given I we also I a the that update the expecting an

So going can you How the within any around turned is the updated expectations? talk to so label there fast? that REMS limit future And potential label additional fit your about updates why does with forward? the any in

we Well, in REMS sense. technical have a don't a

maybe come about thinking with back answer question Joe, you maybe mean you're it, by me the I'll the and REMS. as to what So

going process. The it estimate a that As new a the love to fall -- glad classic we technical were the it the extension And but supplemental. take U.S. we'd the part to agency outside it in treated do also supplemental this could normal Obviously, we we study a like wasn't right? fed as when supplemental more was, conservative pivotal. The So were communicated, application we to substudy it drug data, we a of would much it, that let data great, is. this but the said previously supplemental they FDA. agency we understood And know they your and our see view, luckily performed our biopsy within X package. wasn't supplemental were technically to to were NDA, that in of agency that as potentially NDA we category what packaged months the do going because of probably XX

came positive. And incorporated, was think our we We it hit language biopsy had We expected. there's data the we the this statement substudy through will year which and maybe through publication forms. limiting. pretty not than earlier the more data I say terms removed that expectations, the made So we from a X request everything is incorporated. data indication much still that wanted now guided don't externally, but medical on think than can the in data, we way I and think wanted be information that's drug and that available of

That sense. buyback? what my announced yet? question. buying shares any about back recently makes then progress And you your answers Have made That any

Short answer is yes.

up about an quarter, until we April. just discretionary repurchases flows purchased X.X actually the $XX.X the that's Board's We future end what's total for any While -- of future I is to -- average at million and because through hand, it's discretion. the with shares. On not cash $X.XX, -- equates through worth kind of million until of up I'm the of to cost this stock within about believe look We follow-on and would fund purchases cash question. through the on sure which

the end So more we'll report through of April. XX.X% out as we but go here,

H.C. Wainright. question Arce from coming Ed from is next Your

your the a into on little and again X. particular, got of to group the could, further, bigger picture to have on impact that, lower in you this with long-term to treatment. follow particular, view which that label, up the been particularly you label. eventually got updated of main I speak doctors here you really rheumatologists, particular this I that if bit signs the new have longer-term aspects of with targets In persistent along a you've wanted prescribing couple the in here. the Just a as the label. Peter, campaign, I of the treating which wanted now gather

and perspective those. of longer-term the on thoughts broad impacts Just

is history thing over anybody, drugs, And launched multiple it. terms for on this from the how anti-TNF, a of hedged it those a sure remember actually missed persistency fairly think in XX%. year. seen numbers the move. In at right least much we were improvement at and time sort money to when doing throw we've for of very quarters, staying We long I to of biologics wasn't a we no matter X of I'm below couple last little Well, And but here, we my category our really consistent at up while hard persistency. XX%

XX%. at we're Now

I of used can level, shows having think at C&I used, macro for C&I incredibly can a this on least longer this there periods data is next-generation be that So be out helpful. this that time

alongside And now investment earlier about actually very They've that needing sure diagnosis, very I vocal making treatment, the to about now these people levels think start they're that, but companies you into educating going aggressive play. guidelines have always and and and guidelines into of treatment. fairly are put consistent actually clear. been

signs. longer treated need see the the patient just This there we X guidelines question, is rheumatologists the We Aurinia's in And for when of are to by on this be to need diagnosis should treatment the aggressive is guidelines. So the office. estimated years. goal. term, picture X see of rheumatologist those an proteinuria And then not the estimate levels to bigger more goal target treatment

those and have think move for larger patients much happen. to care significant to all it the going opportunity that going dramatically. level So we're to take whole of the of trying a can I it's down of here for think improvement that's also the And And take for disease industry. what's things I this category burden to

Ed. big picture view least So we that's kind as at of the see it,

if helpful. A That's more, I couple may. Great.

one Just on AURXXX. question

inhibitor. very target, a remains interesting mentioned the You April that BAF

then can development you ask and that? And anything versus prior think previously. about that it share expectations changed particular the of about newer I higher view Just with persisted is XX% you lines the has for comment your time terms XX% to any flow expectations? What pricing, kinase wondering the if you to XX% question, term news near from in the have or last wanted

that have Listen, to one, first two approved on most updated then FDA. think give Yes, I'll give net. XX% U.S. was to I kind of information the the I'll let take the cents IND by just the his AURXXX, the we on XX% Joe and average

So we'll we the goal said And call, ready our start thing studies. SAD/MAD are I moving to is to forward. as on this keep

indications long et when So take do or about Phase in-human to clinical understand to it's soon. internally forward, going you path, how getting first see we your you're and what when and expect have SAD we actually should III studies whether a data, cetera, those when externally Phase studies will data, MAD II have clear in that

animal and an a the studies has by through in I been either approved through one would party. we're that but this IND earmark the Aurinia year, moving So FDA, SAD/MAD U.S. and future call, external know for that or tox into

So question, kick to that the pricing Joe. let me

factors. pricing kind on it, that obviously, your already has One Peter was which time. kind of the follow question, to touched yes, on X it's is, Ed, considerably up persistency itself over of evolved

if QX months. back, of look at was to XX moved It's now at XX% months. XX you about I XX% 'XX, it think

is up estimate. price for evolution couplement net revenue So of have that's our that that probably small largest increases driver average. time number per of kind the the of some patient over inched that Also, on

Our next is from question coming Bloomberg. Martin David from

Yes.

Is could First part there updated is Or claims off, back to the new any LUPKYNIS think? do you to patent change your rise everything that in related label. of also already going give existing to the patents?

publicly FDA. listing. We Orange Patent that that U.S. -- follows can until been terms of we those looking extension are tradeoff And action, the we've regardless the some as sort or I you you file I have have it can leave with with and label that get when line an U.S. patents label we tell of our those would of patents it's we that study not with on Book that in change disclosed started not. to the the mentioned in patents not U.S. possibility back that that of be patents be just now previously, in at on of of file terms David, or U.S. the whether general. on helpful Well, acceptance actually -- won't have and FDA the U.S.

U.S. So short but haven't from yet. answer a PTO is the the readout we had yes,

it. Got

important have with trending do typically on you read up, more LUPKYNIS? occur? a proteinuria becoming long and to have after coming take And patients what of it how rebound percent Second that the does question, for restarts rebound off

I answer would short this. got to is answer clinical The look if -- he's Greg to and a

treated us a the we issue. -- when MMF is a until alignment historical treat terms And is this comes to used This read had alongside the isn't due a of drug and I'm of of that is patients that proteinuria long this it's that how to this are. What the that to some we LUPKYNIS get do I terms percent of as think the patients issue. seeing the and It's internally not data This a issue. have episodically. after in and unfortunately an might we is any in disease, know know drugs disease. that levels LUPKYNIS the quantitative to that what guidelines of toxicity what more sure be treatment fact that come takes of lot back. emerging them on those we they

the to was drugs potentially manage to was aligned you we continuing But would intermittently market put a from as add? more the guidelines. Greg, these as treat on that trying shift answer opportunity an toxic be being trying just the what see patients. pattern to were derived we that So to is this short

the X At in program, proteinuria stability was And for regard the of weeks. we weeks. that AURORA X patient's end subsequent our of monitored with response terms subsequent patients to there for

agree I'll will certainly recurrence treatment secure thing. one recommendations and how implying clinicians hence, at indicate just a disease, is are it area Thereafter, episodic this chronic treat The you this you, different the opinion to not individuals points. And about is irrespective maintain with once emphasize I have like they important. response disease, Peter, leaders that an different in

the of over comments. our like closing floor I'd reach further to the We you. Thank for turn management session. any end or back question-and-answer to

to great as updating a everybody the for you quarter. second forward Have Look into I today. time day. want thank move their we to

webcast. teleconference you. and does That Thank conclude today's

at may and your you participation lines disconnect day. this your have wonderful You We time, today. thank for a